Vaxxinity (VAXX) Competitors

$0.0001 0.00 (0.00%)

As of 05/13/2026 03:12 PM Eastern

VAXX vs. KPRX, CDT, IMNN, GDTC, and PHXM

Should you buy Vaxxinity stock or one of its competitors? MarketBeat compares Vaxxinity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxxinity include Kiora Pharmaceuticals (KPRX), CDT Equity (CDT), Imunon (IMNN), CytoMed Therapeutics (GDTC), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

How does Vaxxinity compare to Kiora Pharmaceuticals?

Vaxxinity (NASDAQ:VAXX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, meaning that its share price is 148% less volatile than the broader market.

In the previous week, Kiora Pharmaceuticals had 3 more articles in the media than Vaxxinity. MarketBeat recorded 3 mentions for Kiora Pharmaceuticals and 0 mentions for Vaxxinity. Kiora Pharmaceuticals' average media sentiment score of 0.72 beat Vaxxinity's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaxxinity	Neutral
Kiora Pharmaceuticals	Positive

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 280.23%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vaxxinity's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has higher revenue and earnings than Vaxxinity. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.71	N/A

Summary

Kiora Pharmaceuticals beats Vaxxinity on 8 of the 14 factors compared between the two stocks.

How does Vaxxinity compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

In the previous week, CDT Equity had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for CDT Equity and 0 mentions for Vaxxinity. CDT Equity's average media sentiment score of 0.47 beat Vaxxinity's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Neutral
Vaxxinity	Neutral

CDT Equity has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, meaning that its stock price is 7,537% less volatile than the broader market.

Vaxxinity is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A

Vaxxinity's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Vaxxinity	N/A	N/A	N/A

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CDT Equity beats Vaxxinity on 6 of the 11 factors compared between the two stocks.

How does Vaxxinity compare to Imunon?

Vaxxinity (NASDAQ:VAXX) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 2.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Imunon has a consensus target price of $10.00, suggesting a potential upside of 280.08%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Vaxxinity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Imunon	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Imunon had 10 more articles in the media than Vaxxinity. MarketBeat recorded 10 mentions for Imunon and 0 mentions for Vaxxinity. Imunon's average media sentiment score of 0.70 beat Vaxxinity's score of 0.00 indicating that Imunon is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaxxinity	Neutral
Imunon	Positive

Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the broader market. Comparatively, Imunon has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Vaxxinity's return on equity of 0.00% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Imunon	N/A	-318.21%	-146.11%

Imunon is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Imunon	N/A	N/A	-$14.49M	-$7.97	N/A

Summary

Imunon beats Vaxxinity on 7 of the 13 factors compared between the two stocks.

How does Vaxxinity compare to CytoMed Therapeutics?

Vaxxinity (NASDAQ:VAXX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

CytoMed Therapeutics has higher revenue and earnings than Vaxxinity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
CytoMed Therapeutics	$324.39K	31.08	-$3.10M	N/A	N/A

In the previous week, CytoMed Therapeutics had 2 more articles in the media than Vaxxinity. MarketBeat recorded 2 mentions for CytoMed Therapeutics and 0 mentions for Vaxxinity. CytoMed Therapeutics' average media sentiment score of 0.67 beat Vaxxinity's score of 0.00 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaxxinity	Neutral
CytoMed Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxxinity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CytoMed Therapeutics beats Vaxxinity on 6 of the 8 factors compared between the two stocks.

How does Vaxxinity compare to PHAXIAM Therapeutics?

Vaxxinity (NASDAQ:VAXX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
PHAXIAM Therapeutics	N/A	N/A	N/A

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
PHAXIAM Therapeutics	Neutral

Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

Vaxxinity and PHAXIAM Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

Get Vaxxinity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VAXX vs. The Competition

Export

Metric	Vaxxinity	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13K	$928.09M	$6.31B	$12.44B
Dividend Yield	N/A	4.84%	2.79%	5.30%
P/E Ratio	0.00	1.53	21.00	25.62
Price / Sales	N/A	117.97	558.69	75.49
Price / Cash	N/A	20.07	42.94	55.34
Price / Book	0.00	8.10	9.84	6.72
Net Income	-$56.93M	-$3.91M	$3.55B	$333.51M
7 Day Performance	N/A	9.85%	-0.18%	0.32%
1 Month Performance	N/A	52.33%	1.54%	4.21%
1 Year Performance	N/A	100.57%	41.14%	36.13%

Vaxxinity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VAXX Vaxxinity	N/A	$0.00 flat	N/A	-50.0%	$13K	N/A	N/A	90
KPRX Kiora Pharmaceuticals	2.4055 of 5 stars	$2.43 -3.0%	$10.00 +310.8%	-15.7%	$10.78M	N/A	N/A	10	Earnings Report
CDT CDT Equity	0.2347 of 5 stars	$2.23 -1.3%	N/A	-99.8%	$10.74M	N/A	N/A	3	Gap Down
IMNN Imunon	2.1495 of 5 stars	$2.72 +0.4%	$132.50 +4,771.3%	-78.3%	$10.67M	N/A	N/A	30	News Coverage Earnings Report
GDTC CytoMed Therapeutics	0.2726 of 5 stars	$0.90 -2.6%	N/A	-66.7%	$10.60M	$250K	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VAXX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaxxinity (VAXX) Competitors

VAXX vs. KPRX, CDT, IMNN, GDTC, and PHXM

How does Vaxxinity compare to Kiora Pharmaceuticals?

Summary

How does Vaxxinity compare to CDT Equity?

Summary

How does Vaxxinity compare to Imunon?

Summary

How does Vaxxinity compare to CytoMed Therapeutics?

Summary

How does Vaxxinity compare to PHAXIAM Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VAXX vs. The Competition

Vaxxinity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaxxinity (VAXX) Competitors

VAXX vs. KPRX, CDT, IMNN, GDTC, and PHXM

How does Vaxxinity compare to Kiora Pharmaceuticals?

Which has more risk & volatility, VAXX or KPRX?

Does the media prefer VAXX or KPRX?

Do analysts recommend VAXX or KPRX?

Do insiders & institutionals believe in VAXX or KPRX?

Is VAXX or KPRX more profitable?

Which has preferable earnings & valuation, VAXX or KPRX?

Summary

How does Vaxxinity compare to CDT Equity?

Does the media favor CDT or VAXX?

Which has more volatility & risk, CDT or VAXX?

Which has stronger earnings & valuation, CDT or VAXX?

Is CDT or VAXX more profitable?

Do institutionals & insiders have more ownership in CDT or VAXX?

Do analysts prefer CDT or VAXX?

Summary

How does Vaxxinity compare to Imunon?

Do institutionals and insiders hold more shares of VAXX or IMNN?

Do analysts recommend VAXX or IMNN?

Does the media refer more to VAXX or IMNN?

Which has more volatility & risk, VAXX or IMNN?

Is VAXX or IMNN more profitable?

Which has preferable valuation and earnings, VAXX or IMNN?

Summary

How does Vaxxinity compare to CytoMed Therapeutics?

Which has more volatility & risk, VAXX or GDTC?

Is VAXX or GDTC more profitable?

Which has preferable earnings and valuation, VAXX or GDTC?

Does the media refer more to VAXX or GDTC?

Do analysts prefer VAXX or GDTC?

Do insiders and institutionals believe in VAXX or GDTC?

Summary

How does Vaxxinity compare to PHAXIAM Therapeutics?

Is VAXX or PHXM more profitable?

Do insiders and institutionals hold more shares of VAXX or PHXM?

Does the media favor VAXX or PHXM?

Which has more risk & volatility, VAXX or PHXM?

Which has stronger earnings and valuation, VAXX or PHXM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VAXX vs. The Competition

Vaxxinity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools